Twist Bioscience
455 Mission Bay Blvd South
San Francisco
California
94158
United States
257 articles with Twist Bioscience
-
Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches
3/9/2023
Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches.
-
Twist Bioscience to Present at Upcoming Investor Conferences - February 28, 2023
2/28/2023
Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences.
-
Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT
2/7/2023
Twist Bioscience Corporation today announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solution focused on non-human genomics applications, at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting in Hollywood, Florida.
-
Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results
2/3/2023
Twist Bioscience Corporation today reported financial results and business highlights for the first quarter of fiscal 2023 ended December 31, 2022.
-
Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future
1/26/2023
Twist Bioscience Corporation announced the shipments of the first products from its second manufacturing site, the Factory of the Future, in Wilsonville, Oregon.
-
Twist Bioscience to Report Fiscal 2023 First Quarter Financial Results on Friday, February 3, 2023
1/19/2023
Twist Bioscience Corporation today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022, before the opening of the market on Friday, February 3, 2023.
-
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
1/10/2023
Twist Bioscience Corporation and Centogene N.V. today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and support diagnostics.
-
Twist Bioscience announced a partnership with Astellas Pharma on Monday, seeking to discover antibodies against several targets to hit on curative therapies for hard-to-treat diseases.
-
Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration
1/9/2023
Twist Bioscience Corporation today announced a research collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) to discover antibodies against multiple targets of interest to develop curative therapies for patients suffering from diseases that lack treatment options.
-
Twist Bioscience to Present at the 41st Annual J.P. Morgan Health Care Conference
1/3/2023
Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 41st Annual J.P. Morgan Health Care Conference on Monday, January 9th at 5:15 p.m. PST / 8:15 p.m. EST.
-
Twist Bioscience to Present at 5th Annual Evercore ISI HealthCONx Conference
11/23/2022
Twist Bioscience Corporation today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 4:20 p.m. Eastern Time.
-
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results
11/18/2022
Twist Bioscience Corporation today reported financial results and business highlights for the fourth quarter and full year fiscal 2022 ended September 30, 2022.
-
Twist Bioscience Addresses Misleading Short-Seller Report
11/15/2022
Twist to report fiscal Q4 and full year 2022 financial results before market Friday, November 18, and host a conference call at 8:00 a.m. Eastern Time.
-
Twist Bioscience to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on Friday, November 18, 2022
11/3/2022
Twist Bioscience Corporation today announced that it will issue its financial results for the fiscal 2022 fourth quarter and full year ended September 30, 2022, before the opening of the market on Friday, November 18, 2022.
-
Twist Bioscience and Illumina Partner to Produce Robust Exome Panel to Advance Research
11/2/2022
Twist Bioscience Corporation and Illumina, Inc. today announced a partnership to provide expanded customer access to the co-branded Twist Bioscience ® for Illumina ® Exome 2.0 Plus panel designed to advance disease research.
-
Twist Bioscience Promotes Patrick Finn, Ph.D., to President and Chief Operating Officer
10/26/2022
Twist Bioscience Corporation today announced the promotion of Patrick Finn, Ph.D. to the newly created position of president and chief operating officer.
-
PacBio and Twist Bioscience Deliver Initial Portfolio of Target Enrichment Panels for HiFi Sequencing
10/19/2022
PacBio (NASDAQ: PACB) and Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of an initial portfolio of off-the-shelf long-read gene panels.
-
Twist Bioscience Earns 2022 Great Place to Work Certification
10/12/2022
Twist Bioscience Corporation today announced that it has earned Great Place to Work ® Certification™ in the U.S. for the second consecutive year, and for the first time in China, Germany, Singapore, and the United Kingdom.
-
Twist Bioscience to Present at JSNN NanoImpacts 2022
10/5/2022
Twist Bioscience Corporation today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at the Joint School of Nanoscience and Nanoengineering (JSNN) NanoImpacts 2022: Semiconductor Synthetic Biology and Beyond taking place October 13-15, 2022.
-
The Australian Research Council Centre of Excellence in Synthetic Biology and Twist Bioscience Partner to Foster and Accelerate Synthetic Biology Research in Australia
9/20/2022
Twist Bioscience (Nasdaq: TWST) and the Australian Research Council (ARC) Centre of Excellence in Synthetic Biology (CoESB) today announced a partnership that will enable CoESB members and partners to order a wide range of Twist products that facilitate research and development.